Roberts, C. J. C. published the artcileComparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, the main research area is diuretic tienilate uricosuric antihypertensive; urate blood tienilate diuretic.
In a double-blind cross-over study, 13 previously untreated hypertensive patients were treated orally for 30 days with tienilic acid (I) [40180-04-9], bendrofluazide (II) [73-48-3], or spironolactone (III) [52-01-7], 250, 5, and 100 mg resp.; II caused the greatest natriuresis on the first treatment day, and the most rapid fall in blood pressure. The ultimate antihypertensive effects of I, II, and III were similar. I caused a reduction in serum urate concentrations, and rise in urate clearance, but II and III caused slight urate retention. I and II caused decreases, and III caused an increase in plasma K concentration No untoward effects were observed from I, II, or III. I is thus a moderately potent diuretic which lowers plasma urate concentrations and may be the drug of first choice for hypertensive patients who either already have gout, or are likely to develop it when taking thiazide diuretics.
British Medical Journal published new progress about Antihypertensives. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid.
Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem